title: OPC-28326, a selective femoral arterial vasodilator, augments ischemia induced angiogenesis.
abstract: OPC-28326, 4-(N-methyl-2-phenylethylamino)-1-(3,5-dimethyl-4-propionyl-aminobenzoyl) piperidine hydrochloride monohydrate, is a newly developed selective peripheral vasodilator and increases blood flow to lower extremities with alpha2-adrenergic antagonist property. Here, we investigated the effect of OPC-28326 on ischemia-induced angiogenesis. OPC-28326 enhanced tube formation by human aortic endothelial cells (HAECs). Moreover, OPC-28326 enhanced the number of microvessels sprouting from aortic rings embedded in collagen gel. OPC-28326 markedly induced phosphorylation of endothelial nitric oxide synthase (eNOS) in HAECs via phosphatidylinositol-3 kinase PI3K/Akt (PI3K/Akt) pathway. Next, the angiogenic effect of OPC-28326 was evaluated in a mouse hindlimb ischemia model. Blood flow recovery to the ischemic leg was significantly enhanced by OPC-28326. Furthermore, anti-CD31 immunostaining revealed that OPC-28326 increased capillary density in the ischemic muscle. However, OPC-28326 failed to promote blood flow recovery in ischemic hindlimb in eNOS-deficient mice. These results suggest that OPC-28326 promotes angiogenesis, which was associated with activation of eNOS via PI3K/Akt pathway. OPC-28326 might be promising to treat patients with ischemic vascular diseases.
authors.affiliation: Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Sumi
authors.forename: Masataka
authors.initials: M
authors.lastname: Sata
authors.forename: Ayako
authors.initials: A
authors.lastname: Hashimoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Imaizumi
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
authors.forename: Takao
authors.initials: T
authors.lastname: Ohki
authors.forename: Toyoki
authors.initials: T
authors.lastname: Mori
authors.forename: Ryozo
authors.initials: R
authors.lastname: Nagai
mesh_terms: D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D001011:Aorta / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D015153:Blotting, Western; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology; D006614:Hindlimb / Q000098:blood supply; D006801:Humans; D066298:In Vitro Techniques; D007511:Ischemia / Q000503:physiopathology*; D017078:Laser-Doppler Flowmetry; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D012039:Regional Blood Flow; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D000814:Aniline Compounds; D010880:Piperidines; D014665:Vasodilator Agents; D052250:Nitric Oxide Synthase Type III; C400276:OPC 28326